Is IPSC or ACRV more profitable?

Century Therapeutics' return on equity of -49.51% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% Acrivon Therapeutics N/A -70.14% -61.60%

Does the media prefer IPSC or ACRV?

In the previous week, Acrivon Therapeutics had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.64 beat Acrivon Therapeutics' score of -0.21 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acrivon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ACRV or SABS more profitable?

SAB Biotherapeutics' return on equity of -6.74% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% SAB Biotherapeutics N/A -6.74% -6.06%

Is ACRV or SGMT more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -70.14% -61.60% Sagimet Biosciences N/A -31.96% -30.57%

Does the media favor ACRV or SGMT?

In the previous week, Acrivon Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.69 beat Acrivon Therapeutics' score of -0.21 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NLTX or ACRV?

Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 510.86%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, NLTX or ACRV?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Acrivon Therapeutics N/A N/A -$77.90M -$1.88 N/A

Is NLTX or ACRV more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Acrivon Therapeutics N/A -70.14% -61.60%

Does the media refer more to AGEN or ACRV?

In the previous week, Acrivon Therapeutics had 3 more articles in the media than Agenus. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 3 mentions for Agenus. Agenus' average media sentiment score of 0.06 beat Acrivon Therapeutics' score of -0.21 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Acrivon Therapeutics (ACRV) Competitors

$2.21 +0.01 (+0.45%)

As of 08/21/2026 04:00 PM Eastern

Compare

ACRV vs. IPSC, SABS, SGMT, NLTX, and AGEN

Should you buy Acrivon Therapeutics stock or one of its competitors? Acrivon Therapeutics's main competitors and comparable companies include Century Therapeutics (IPSC), SAB Biotherapeutics (SABS), Sagimet Biosciences (SGMT), Neoleukin Therapeutics (NLTX), and Agenus (AGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acrivon Therapeutics compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Acrivon Therapeutics had 4 more articles in the media than Century Therapeutics. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 0.64 beat Acrivon Therapeutics' score of -0.21 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$109.16M	3.43	-$9.58M	-$0.93	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 2.4% of Century Therapeutics shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Century Therapeutics' return on equity of -49.51% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Century Therapeutics presently has a consensus target price of $4.75, suggesting a potential upside of 129.47%. Acrivon Therapeutics has a consensus target price of $13.50, suggesting a potential upside of 510.86%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Century Therapeutics and Acrivon Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to SAB Biotherapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Acrivon Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

In the previous week, Acrivon Therapeutics had 6 more articles in the media than SAB Biotherapeutics. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 0 mentions for SAB Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.00 beat Acrivon Therapeutics' score of -0.21 indicating that SAB Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Acrivon Therapeutics	Neutral
SAB Biotherapeutics	Neutral

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Acrivon Therapeutics currently has a consensus target price of $13.50, suggesting a potential upside of 510.86%. SAB Biotherapeutics has a consensus target price of $12.00, suggesting a potential upside of 217.46%. Given Acrivon Therapeutics' higher possible upside, research analysts clearly believe Acrivon Therapeutics is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

SAB Biotherapeutics has higher revenue and earnings than Acrivon Therapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
SAB Biotherapeutics	$1.32M	260.56	$13.27M	-$1.30	N/A

SAB Biotherapeutics' return on equity of -6.74% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

Summary

SAB Biotherapeutics beats Acrivon Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Sagimet Biosciences?

Acrivon Therapeutics (NASDAQ:ACRV) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Acrivon Therapeutics currently has a consensus target price of $13.50, suggesting a potential upside of 510.86%. Sagimet Biosciences has a consensus target price of $29.17, suggesting a potential upside of 184.55%. Given Acrivon Therapeutics' higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Acrivon Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the broader market.

In the previous week, Acrivon Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 4 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.69 beat Acrivon Therapeutics' score of -0.21 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sagimet Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences has higher revenue and earnings than Acrivon Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A
Sagimet Biosciences	$2M	318.57	-$51.04M	-$1.28	N/A

71.6% of Acrivon Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 10.5% of Acrivon Therapeutics shares are held by company insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sagimet Biosciences' return on equity of -31.96% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-70.14%	-61.60%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Summary

Sagimet Biosciences beats Acrivon Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Neoleukin Therapeutics' return on equity of -37.22% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market.

Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 510.86%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Acrivon Therapeutics had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Acrivon Therapeutics' score of -0.21 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Acrivon Therapeutics	Neutral

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Acrivon Therapeutics beats Neoleukin Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Agenus?

Agenus (NASDAQ:AGEN) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Agenus has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

In the previous week, Acrivon Therapeutics had 3 more articles in the media than Agenus. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 3 mentions for Agenus. Agenus' average media sentiment score of 0.06 beat Acrivon Therapeutics' score of -0.21 indicating that Agenus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.5% of Agenus shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Agenus has a net margin of 69.33% compared to Acrivon Therapeutics' net margin of 0.00%. Agenus' return on equity of -47.68% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	69.33%	-47.68%	57.73%
Acrivon Therapeutics	N/A	-70.14%	-61.60%

Agenus has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	3.19	$120K	$2.58	3.14
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$1.88	N/A

Agenus currently has a consensus price target of $19.50, indicating a potential upside of 141.04%. Acrivon Therapeutics has a consensus price target of $13.50, indicating a potential upside of 510.86%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Agenus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Agenus beats Acrivon Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.71M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-1.18	11.62	272.33	24.21
Price / Sales	N/A	1,341.06	625.25	96.46
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	0.62	17.38	11.25	6.42
Net Income	-$77.90M	-$22.72M	$3.47B	$348.89M
7 Day Performance	13.33%	3.29%	2.09%	0.08%
1 Month Performance	32.34%	8.23%	6.64%	3.88%
1 Year Performance	62.50%	55.05%	25.02%	16.98%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	3.1213 of 5 stars	$2.21 +0.5%	$13.50 +510.9%	+62.5%	$94.71M	N/A	N/A	58
IPSC Century Therapeutics	1.7959 of 5 stars	$1.95 -0.3%	$4.75 +144.2%	+282.5%	$350.78M	$109.16M	N/A	170
SABS SAB Biotherapeutics	2.0912 of 5 stars	$3.80 +0.7%	$12.00 +216.2%	+75.0%	$345.31M	$1.32M	N/A	140	Positive News Analyst Upgrade
SGMT Sagimet Biosciences	2.8598 of 5 stars	$10.59 +1.5%	$29.17 +175.5%	+44.2%	$344.88M	N/A	N/A	8
NLTX Neoleukin Therapeutics	N/A	$36.68 +1.5%	N/A	+95.6%	$344.72M	N/A	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. IPSC, SABS, SGMT, NLTX, and AGEN

How does Acrivon Therapeutics compare to Century Therapeutics?

Summary

How does Acrivon Therapeutics compare to SAB Biotherapeutics?

Summary

How does Acrivon Therapeutics compare to Sagimet Biosciences?

Summary

How does Acrivon Therapeutics compare to Neoleukin Therapeutics?

Summary

How does Acrivon Therapeutics compare to Agenus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. IPSC, SABS, SGMT, NLTX, and AGEN

How does Acrivon Therapeutics compare to Century Therapeutics?

Does the media prefer IPSC or ACRV?

Which has higher earnings and valuation, IPSC or ACRV?

Which has more volatility & risk, IPSC or ACRV?

Do institutionals & insiders hold more shares of IPSC or ACRV?

Is IPSC or ACRV more profitable?

Do analysts rate IPSC or ACRV?

Summary

How does Acrivon Therapeutics compare to SAB Biotherapeutics?

Which has more volatility & risk, ACRV or SABS?

Does the media favor ACRV or SABS?

Do institutionals and insiders have more ownership in ACRV or SABS?

Do analysts prefer ACRV or SABS?

Which has stronger earnings & valuation, ACRV or SABS?

Is ACRV or SABS more profitable?

Summary

How does Acrivon Therapeutics compare to Sagimet Biosciences?

Do analysts prefer ACRV or SGMT?

Which has more volatility and risk, ACRV or SGMT?

Does the media favor ACRV or SGMT?

Which has higher valuation and earnings, ACRV or SGMT?

Do insiders & institutionals have more ownership in ACRV or SGMT?

Is ACRV or SGMT more profitable?

Summary

How does Acrivon Therapeutics compare to Neoleukin Therapeutics?

Is NLTX or ACRV more profitable?

Which has stronger earnings & valuation, NLTX or ACRV?

Which has more volatility & risk, NLTX or ACRV?

Do analysts prefer NLTX or ACRV?

Does the media favor NLTX or ACRV?

Do insiders and institutionals have more ownership in NLTX or ACRV?

Summary

How does Acrivon Therapeutics compare to Agenus?

Which has more volatility and risk, AGEN or ACRV?

Does the media refer more to AGEN or ACRV?

Do institutionals and insiders believe in AGEN or ACRV?

Is AGEN or ACRV more profitable?

Which has preferable valuation & earnings, AGEN or ACRV?

Do analysts rate AGEN or ACRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools